Views & Analysis | Perspectives on pharma industry issues

Market Access

pharma commercialisation concept - hcp and laptop and metrics

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.

Sales & Marketing

Sponsored

Solution Spotlight: DHL Supply Chain’s Pharma Specialized Ne...

The Pharma Specialized Network (PSN) provides a globally integrated solution for delivering end-to-end distribution to clinical sites, laboratories, hospitals, and patients.

Patients

A hand grabs and breaks a DNA chain to represent biohacking

Why biohackers are ditching vague health metrics

Precision diagnostics enable targeted therapeutics.

Market Access

Anglonordic Life Science 2026: A focus on execution

The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.

Digital

Sponsored

12 Questions With Navdeep "Navi" Chadha

Navdeep "Navi" Chadha is co-founder & CTO of Axtria, a global provider of AI-powered data analytics and cloud software for the life sciences industry.

Market Access

How do we make patient centricity a reality?

For years, the subject of fostering direct connections with patients has been highlighted by notable figures across the healthcare and life sciences industries as a key feature to be explor

Patients

Representation in UK pharma: A progress report

Pharma understands that building equitable health services starts with building equitable institutions.

Oncology

At ESMO, three studies show promise of antibody-drug conjuga...

The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, as breast cancer researchers c

Sales & Marketing

Sponsored

Solution Spotlight: DHL Supply Chain’s Pharma Specialized Ne...

The Pharma Specialized Network (PSN) provides a globally integrated solution for delivering end-to-end distribution to clinical sites, laboratories, hospitals, and patients.

Sales & Marketing

pharmaphorum podcast Episode 257, John Holodnak, Occam

A philosophical look at market turn in the Age of AI, with J...

John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.

Digital

Sponsored

12 Questions With Navdeep "Navi" Chadha

Navdeep "Navi" Chadha is co-founder & CTO of Axtria, a global provider of AI-powered data analytics and cloud software for the life sciences industry.

Digital

The augmented marketer: Fusing AI and human expertise in lif...

Predictive AI is not replacing human expertise, but augmenting it.

Market Access

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.

Market Access

Anglonordic Life Science 2026: A focus on execution

The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Patients

Why biohackers are ditching vague health metrics

Precision diagnostics enable targeted therapeutics.

Patients

Hands in a circle point to the middle where EU stars are, blue background

Stronger together: The future of psychiatry in a changing Eu...

Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.

Patients

More than a discount: How intelligent copay programmes are r...

Brian Laird explains a more dynamic, data-driven approach to copay is redefining affordability, creating a new standard for balancing patient support.

R&D

Podcast interview with Boyang Wang, the founder of Immortal Dragons

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Solution Spotlight: DHL Supply Chain’s Pharma Specialized Ne...

Why biohackers are ditching vague health metrics

Anglonordic Life Science 2026: A focus on execution

12 Questions With Navdeep "Navi" Chadha

How do we make patient centricity a reality?

Representation in UK pharma: A progress report

At ESMO, three studies show promise of antibody-drug conjuga...

Solution Spotlight: DHL Supply Chain’s Pharma Specialized Ne...

A philosophical look at market turn in the Age of AI, with J...

12 Questions With Navdeep "Navi" Chadha

The augmented marketer: Fusing AI and human expertise in lif...

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Anglonordic Life Science 2026: A focus on execution

From promise to practice: What must happen next for genetic ...

LSX2026: Addressing adult eye cancer, with Roi Raz

From preclinical toxicology to clinical safety: The path for...

Why biohackers are ditching vague health metrics

Stronger together: The future of psychiatry in a changing Eu...

More than a discount: How intelligent copay programmes are r...

Why everyone should care about longevity, with Boyang Wang

Beyond proof of concept: Alzheimer’s and the next chapter of...

Changing Faces: Board of Directors and Advisory Boards, Marc...

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks